GRIN2B and neurodegenerative disease: Thus, the radioligand enables longitudinal studies investigating the GluN2B-subunit NMDAR for drug development, interventional studies and alterations in neuropsychiatric disorders including neurodegenerative diseases under the commonly applied regulations of the RDRC and the ICRP guidelines.